Delving into the Latest Updates on Schwarz Pharma, Inc. with Synapse

概览

关联

2

项与 Schwarz Pharma, Inc. 相关的药物

Rotigotine

罗替高汀

靶点

D2 receptor

作用机制

D2 receptor激动剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

欧盟 [+3]

首次获批日期2006-02-15

Chlorpheniramine Maleate/Pseudoephedrine Hydrochloride

马来酸氯苯那敏/盐酸伪麻黄碱

靶点

H1 receptor x α-adrenergic receptor

作用机制

H1 receptor拮抗剂 [+1]

在研机构-

原研机构

Schwarz Pharma, Inc.

在研适应症-

非在研适应症

普通感冒

最高研发阶段撤市

首次获批国家/地区

美国

首次获批日期1985-03-18

6

项与 Schwarz Pharma, Inc. 相关的临床试验

CTR20130957 / Completed临床1期

一项单中心、单剂量和多剂量研究以评价罗替高汀透皮贴片在中国健康受试者中的药代动力学、安全性和耐受性

评价罗替高汀在中国健康受试者中单剂量和多剂量给药后未结合罗替高汀和总罗替高汀的PK特性，安全性和耐受性

开始日期2012-08-06

申办/合作机构

Schwarz Pharma Produktions GmbH

[+3]

CTR20131225 / Completed临床3期

晚期帕金森病受试者中研究罗替高汀疗效和安全性试验的多中心、随机、双盲、平行、安慰剂对照研究

本研究的主要目的旨在证实罗替高汀透皮贴剂作为一种辅助治疗对中国晚期特发性帕金森病受试者有效。次要目的旨在证实罗替高汀透皮贴剂在相同患者群中的安全性和耐受性。

开始日期2012-08-03

申办/合作机构

Schwarz Pharma Produktions GmbH

[+3]

CTR20130961 / Completed临床3期

早期特发性帕金森病受试者中研究罗替高汀疗效和安全性的多中心、随机、双盲、安慰剂对照研究

研究的主要目的旨在证实罗替高汀透皮贴剂对中国早期特发性帕金森病受试者有效。次要目的旨在证实罗替高汀透皮贴剂在该患者人群中的安全性和耐受性。

开始日期2012-06-30

申办/合作机构

Schwarz Pharma Produktions GmbH

[+3]

100 项与 Schwarz Pharma, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Schwarz Pharma, Inc. 相关的专利（医药）

登录后查看更多信息

2

项与 Schwarz Pharma, Inc. 相关的文献（医药）

2000-05-01·Pharmaceutical Science & Technology Today

Optimal process design for the manufacture of transdermal drug delivery systems

Article

作者: Wolff

In a pharmaceutical market characterized by increasing competition, assessment criteria related to system design are assuming greater importance. This is true for both conventional dosage forms and drug delivery systems (DDS), as manufacturers strive to achieve adequate patient convenience and compliance. At the same time, the process design for the manufacture of DDS must comply with current good manufacturing practices, and give sufficient consideration to associated environmental issues. Related problems must be solved under social and safety pressures, which, in turn, become economic pressures, such as the consideration of control methods. In addition, both the system design and the process design have a major impact on the cost of goods, as well as on the levels of complexity or risk associated with development.

1995-04-01·Antiviral Chemistry and Chemotherapy

Characterization of the Antiviral Activity of Highly Substituted Pyrroles: A Novel Class of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitor

作者: Antonucci, T. ; Nickell, D. G. ; Warmus, J. S. ; Hodges, J. C.

As a result of mass screening of the Parke-Davis Pharmaceutical compound library for inhibitors of HIV-1 reverse transcriptase (RT) activity, a novel class of inhibitor, the pyrroles, was identified. Subsequently, a series of analogues was screened for inhibitory activity against HIV-1 and some structure-activity relationships were identified. Further characterization of the most potent pyrrole involved comparing its effects in peripheral blood lymphocytes (PBLs) with its effects in transformed cell lines; the pyrrole had the same efficacy (EC50 = approximately 2 μM) but was less toxic in PBLs (IC50 = 175 μM) than in the cell lines CEM-SS and MT-2 (IC50 = 60-70 μM). The pyrrole was active against a strain of HIV-1 resistant to AZT (strain G9106) but lost activity against both HIV-2 (strain ROD) and a strain of HIV-1 resistant to a non-nucleoside reverse transcriptase inhibitor (the pyridinone-resistant strain A17). Moreover, in direct enzymatic testing against HIV-1 RT purified from virus particles and against RT expressed recombinantly, the pyrrole showed potent inhibitory activity. We conclude that the pyrroles present a novel class of HIV-1 non-nucleoside reverse transcriptase inhibitor.

100 项与 Schwarz Pharma, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Schwarz Pharma, Inc. 相关的转化医学

登录后查看更多信息